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Abstract
Background:  The hepatitis C virus (HCV) is a major cause of drug-related morbidity and
mortality, with incidence data implicating a wide range of HCV transmission risk practices. The
Blood-Borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ) is a content valid
instrument that comprehensively assesses HCV risk practices. This study examines the properties
of a new weighted BBV-TRAQ designed to quantify HCV transmission risk among injecting drug
users (IDU).
Methods: Analyses of cross-sectional surveys of Australian IDU (N = 450) were used to generate
normative data and explore the properties of a weighted BBV-TRAQ. Items weights were assigned
according to expert key informant ratings of HCV risk practices performed during the
development stages of the BBV-TRAQ. A range of item weights was tested and psychometric
properties explored. A weighting scheme was recommended based on the plausibility of normative
subscale data in relation to research evidence and the ability of BBV-TRAQ scores to discriminate
between HCV positive and negative participants.
Results: While retaining the psychometric properties of the unweighted scale and demonstrating
good internal reliability. By taking into account the relative transmission risk of a broad range of
putative HCV practices, the weighted BBV-TRAQ produced promising predictive validity results
among IDU based on self-report HCV status, particularly among young and less experienced
injectors.
Conclusion: Brief, easy to administer and score, and inexpensive to apply, the utility of the BBV-
TRAQ for community based education and prevention is enhanced by the application of item
weights, potentially offering a valid surrogate measure for HCV infection among IDU.
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Background
As a leading notifiable disease and a major cause of drug
related morbidity and mortality, it is well recognised that
the hepatitis C virus (HCV) poses a significant public
health challenge. In addition to quality of life impairment
at all disease stages [1,2], most individuals exposed to
HCV become chronically infected (and infectious), with
10–20% developing cirrhosis or hepatocellular carcinoma
[3].
In many countries the majority of HCV prevalence cases
are comprised of current or former injecting drug users
(IDU; [4-6]). Incidence data implicates a wider range of
HCV transmission risk practices (e.g., environmental con-
tamination) and injecting paraphernalia (e.g., spoon, fil-
ter, water, swab) other than the sharing of used syringes
[7,8].
Such findings, in the context of continuing high preva-
lence of injecting risk behaviour [6,9-11] and HCV infec-
tion [12-14], suggest that controlling the spread of HCV is
dependent on preventing transmission within the IDU
population [8]. Although social and structural determi-
nants of drug use and 'risk' are important to this end [15],
HCV transmission is unlikely to be reduced without sig-
nificant changes in the specific behaviours believed
responsible for the spread of the virus [16]. Reductions in
the prevalence of risk behaviours is therefore a necessary
component of prevention responses and require an
expansion of existing strategies through improved educa-
tion and support for IDU [17].
One of the challenges in HCV surveillance and prevention
rests with evaluating the efficacy of the broad range of
interventions designed to reduce the prevalence of high-
risk practices and, ultimately, rates of HCV seroconver-
sion. To monitor HCV incidence, evaluate intervention
efficacy or clarify the significance of putative/theoretical
risk practices, longitudinal cohort studies represent a gold
standard of evidence. These studies, however, are expen-
sive to conduct and difficult to complete successfully in
community-based samples (and therefore less likely to be
funded in some jurisdictions) because high HCV preva-
lence and incidence rates in IDU necessitate the serial test-
ing of very large numbers of participants. The capacity of
current surveillance mechanisms are therefore impeded in
terms of their capacity to evaluate prevention initiatives
and identify HCV transmission risk practices that contrib-
ute most to new infections. This not only poses a signifi-
cant barrier at the level of nationwide population
prevention programs, but also for the multitude of local
community and agency specific HCV prevention pro-
grams.
An alternative approach to sero-incident studies that is
arguably better suited to local community level HCV pre-
vention and evaluation is to assess participation in high-
risk practices for HCV transmission. Until recently, this
has been complicated by the lack of a standardised instru-
ment capable of reliably measuring participation in a suf-
ficiently broad range of injecting and other putative risk
practices associated with HCV transmission. Although
some injecting risk measures [18,19] demonstrate accept-
able reliability and validity [20,21], they have poor con-
tent validity for HCV monitoring purposes due to
insufficient coverage of the full range of HCV risk prac-
tices.
The predominant mode of HCV transmission is via risky
injecting drug use practices [12,22]. Evidence also impli-
cates tattoos playing a role in the spread of HCV, particu-
larly those performed by non-professionals and/or in
prison settings [23-26]. Sexual transmission of HCV is
highly debated [27,28]. Although some methodologically
suspect studies have suggested an 'appreciable' risk of sex-
ually transmitted HCV [29], recent prospective cohort
studies with considerable person-years of follow-up have
concluded the risk to be extremely low and perhaps non-
existent [30,31]. The risk of horizontal household trans-
mission of HCV is also suggested to be similarly low
[32,33].
The Blood-Borne Virus Transmission Risk Assessment Ques-
tionnaire (BBV-TRAQ) is a standardised content and con-
struct valid instrument offering comprehensive
assessment of injecting, sex and skin penetration risk prac-
tices for HCV, HBV, and HIV [34,35] and has been trans-
lated by the World Health Organisation into eight
languages [36]. Although the comprehensive nature of the
risk practices canvassed in the BBV-TRAQ is an advantage,
each of these practices ultimately contribute equally to
BBV-TRAQ scores, despite evidence suggesting they carry
markedly different relative risks of transmitting a blood-
borne virus (BBV).
This limitation makes it difficult for the current format
BBV-TRAQ to offer a genuine and practical indication of
the risk of contracting a BBV. This paper reports on the
application of a weighting scheme for BBV-TRAQ items to
take account of the relative risks associated with different
risk practices. The analyses undertaken in this paper focus
on HCV by providing initial normative data of HCV trans-
mission risk among a sample of IDU, and explores the
properties of the weighted scale to approximate overall
HCV transmission risk in this group. IDU constitute the
main HCV sero-prevalent and sero-incident risk group in
many countries and constitute the population from which
the BBV-TRAQ was originally developed. Thus this popu-Harm Reduction Journal 2008, 5:12 http://www.harmreductionjournal.com/content/5/1/12
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lation was a logical choice from which to begin the itera-
tive process of scale refinement described in this paper.
Methods
Design
Cross-sectional survey data of IDU was used to examine
the properties of the weighted BBV-TRAQ. This data was
collected between September 1999 and March 2000 as
part of the Australian Blood-Borne Virus Risk and Inject-
ing Drug Use Study (ABRIDUS; [37]). The aim of
ABRIDUS was to measure the extent of specific HCV risk
practices among IDU and explore the contextual determi-
nants of these practices. The survey contained three sec-
tions: demographic information including history of drug
use and self-report HIV, HCV, and HBV status; the BBV-
TRAQ; and a semi-structured component investigating
participants' usual injecting context in relation to inject-
ing risk practices. The BBV-TRAQ was self-completed by
participants in the presence of a research assistant, with
other survey sections administered by research assistants.
Ethics approval for ABRIDUS was granted by Curtin Uni-
versity Ethics Committee, University of NSW Ethics Com-
mittee and the Victorian Department of Human Services
Ethics Committee. Full details of the methods used in
ABRIDUS are described elsewhere [37].
Participants and sampling
Participants were recruited in Melbourne (n = 150), Syd-
ney (n = 150), and Perth (n = 150) and selected on the
basis of having injected drugs at least monthly for the past
six months. A targeted sampling strategy was used,
whereby sample stratification was used to ensure that ade-
quate numbers of females, IDU aged less than 25 years,
and drug treatment naive participants were recruited (at
least one third of each). Participants were recruited
through Needle and Syringe Programs, drug and alcohol
services, youth services, drug user groups, and snowball
methods in each capital city.
Weighting of BBV-TRAQ items
Item weights were assigned according to expert key
informant ratings of HCV risk practices performed during
the development stages of the BBV-TRAQ to help establish
the construct validity of the scale [34]. Key informants
were asked to rate items according to their relative risk of
transmitting HCV on a scale between 0 (no risk) and 10
(highest risk). Median item ratings were then categorised
into five groups used to assign item weights according to
relative HCV transmission risk (see Table 1).
There are evident challenges in attempting to apply empir-
ical weights to scale items when there is a paucity of
empirical data describing the relative risk associated with
the specific practices described in those items. For exam-
ple, what is the increased risk associated with, for exam-
ple, sharing a needle and syringe over sharing other
injecting equipment? To embark on a process of instru-
ment refinement, an essential but habitually neglected
process of improving a scale's representation of a con-
struct [38], we examined the application of three weight-
ing schemes applied to items within each of the five risk
categories shown in Table 1. Log one (weights ranging
from one to five for each risk category respectively); log
two (weights of one, two, four, eight and 16 for each risk
category respectively); and log five (weights of one, five,
25, 125 and 625 for each risk category respectively).
Analysis
Detailed descriptions of the original BBV-TRAQ scoring
system are reported elsewhere [34,39]. Only participants
that answered all BBV-TRAQ questions were included. In
this study, weights were applied to scores for each BBV-
TRAQ item and then summed according to the factor
structure derived from the original BBV-TRAQ develop-
ment. Final weighted scores were obtained for injecting,
other skin penetration, and sex subscales, and for the total
scale [35]. Univariate descriptive statistics were generated
for unweighted and weighted subscale and total scores.
Internal reliability was calculated for subscale and total
scores using standardised item alpha. This internal con-
sistency coefficient is preferred when individual items
have different variances, with Cronbach's alpha being
adversely affected by heterogeneity of item variances [40],
and is appropriate here as individual items within sub-
scales are weighted differently (thus producing marked
differences in item variances). One-way ANOVA assessed
differences in BBV-TRAQ scores according to the self-
reported HCV status of IDUs ("HCV positive", "negative",
"never tested", "don't know"). In an attempt to limit tem-
poral biases of recent engagement in risk behaviours with
HCV status, this between groups analysis was repeated
across study sub-samples (i.e., time since first injected and
age) to examine the stability of results among more recent
initiates or less experienced injectors. Between groups
analyses were also conducted on unweighted and
weighted scores to explore the sensitivity of results to dif-
ferent weighting structures. Data were analysed using the
SPSS Statistical Software Package Release 11.5.0.
Results
Sample profile
Of the 450 IDU surveyed in ABRIDUS, 419 (93%) com-
pleted all BBV-TRAQ items Melbourne (n = 142), Sydney
(n = 133), and Perth (n = 144). Demographic and drug
use characteristics of these participants are presented in
Table 2. The sample was predominantly male and unem-
ployed, most were heroin injectors, injected daily or more
often, and had first injected drugs more than three years
earlier. Nearly half (45%) the sample reported previouslyHarm Reduction Journal 2008, 5:12 http://www.harmreductionjournal.com/content/5/1/12
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Table 1: BBV-TRAQ item categorisations and median key informant ratings
Item Description Median Rating
Category 5 (highest risk; median KE ratings 9–10)
a5 In the last month, how many times have you injected a drug which has been filtered through another persons filter 9
a7 In the last month, how many times have you injected a drug prepared with water that had been used by another person 9
a8 In the last month, how many times have you injected a drug which had come into contact with another person's used needle 
and syringe
9
a13a In the last month how many times have you injected with another person's used needle and syringe
a13b On those occasions, how often did you rinse it with a combination of full-strength bleach and water (2 × 2) before you used it
10
a14 In the last month how many times have you injected with a needle and syringe after another person has already injected 
some of its contents.
10
a19 In the last month, how many times have you received an accidental needle-stick from another person's used needle and 
syringe
9
a20a In the last month, how many times have you reused a needle and syringe taken out of a shared sharps container
a20b On those occasions, how often did you rinse it with a combination of full-strength bleach before you re-used it
10
c2 In the last month, how many times have you been tattooed by someone who was not a professional tattooist 9
c3 In the last month, how many times have you been pierced by someone who was not a professional piercer 10
Category 4 (median KE ratings 7–8)
a6a In the last month, how many times have you injected a drug that was prepared in another persons used spoon or mixing 
container
a6b On those occasions how often did you clean the spoon or mixing container before using it
7
a9a In the last month, how many times have you injected a drug prepared immediately after assisting another person with their 
injection (injecting them, holding their arm, handling used fits, wipe blood away etc)
a9b On those occasions, how often did you wash your hands before preparing your mix
8
a10a In the last month, how many times have you injected a drug that was prepared by another person who had already injected 
or assisted someone else to inject
a10b On those occasions, how often did the person wash your hands before preparing your mix
7
a11a In the last month, how many times have you been injected by another person who had already injected or assisted in 
someone else's injection
a11b On those occasions, how often did the person injecting you wash your hands before injecting you
Not rated
a12a In the last month, how many times have you been injected with a needle and syringe which had been handled or touched by 
another person who had already injected
a12b On those occasions, how often did they wash their hands prior to handling the needle and syringe that you used
7
a15a In the last month, how many times have you touched your own injection site soon after 'assisting' another person with their 
injection
a15b On those occasions, how often did you wash your hands before touching your injection site
8
a16a In the last month, how many times has another person touched your injection site
a16b On those occasions, how often did they wash their hands before touching your injection site
8
a17 In the last month, how many times have you wiped your own injection site with an object (swab, tissue, hanky) which had 
been used by another person
8
c4 In the last month, how many times have you used another person's used razor 7
Category 3 (median KE ratings 5–6)
a1 In the last month, how many times handled another persons syringe at a time when you had cuts etc 6
a18 In the last month, how many times have you used a tourniquet which had been used by another person 6
b2 In the last month, how many times have you engaged in unprotected vaginal sex with another person during menstruation 5
c1 In the last month, how many times have you come in contact with another person's blood (fights, slash-ups, accidents, blood 
nose etc)
5
Category 2 (median KE ratings 3–4)
a2 In the last month, how many times have you sucked or licked left-over drugs from spoon, mixing container used by another 
person
3
a3 In the last month, how many times have you sucked or licked a filter used by another person 3
a4 In the last month, how many times have you sucked or licked a plunger after using it in a mix used by another person 2.5
b3 In the last month, how many times have you engaged in unprotected vaginal sex with another person without lubrication 3
b4 In the last month, how many times have you engaged in unprotected anal sex with another person 4
c5 In the last month, how many times have you used another person's toothbrush 4Harm Reduction Journal 2008, 5:12 http://www.harmreductionjournal.com/content/5/1/12
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testing positive for hepatitis C, 14% reported previously
testing positive for hepatitis B, and reported HIV preva-
lence was very low (2%). There were no systematic differ-
ences in the characteristics of those that completed all
BBV-TRAQ items and those that did not.
Table 3 presents sample descriptive statistics comparing
original and weighted BBV-TRAQ scores. Both the
weighted and unweighted scales produced positively
skewed data with modes for total and subscale scores of
zero (participants reporting no risk behaviours).
Reliability of the weighted BBV-TRAQ
Standardised item alphas were consistent across weight-
ing schemes, showing good internal reliability for the
total BBV-TRAQ (α = .89) injecting (α = .87) and sex (α =
.89) sub-scales. A lower alpha coefficient was obtained for
the other skin penetration (α = .49) subscale.
Validity of the weighted BBV-TRAQ
Key expert rankings of items used in the original BBV-
TRAQ established the construct validity of the scale [35].
Total and subscale weighted and unweighted BBV-TRAQ
scores were compared between groups of participants
c6 In the last month, how many times have you used another person's personal hygiene equipment (nail file, nail scissors, brush 
etc)
3
Category 1 (lowest risk; median KE ratings 1–2)
b1 In the last month, how many times have you engaged in unprotected vaginal sex with another person 1
b5 In the last month, how many times have you engaged in unprotected oral sex with another person 1
b6 In the last month, how many times have you engaged in unprotected manual sex with another person during menstruation 2
b7 In the last month, how many times have you engaged in unprotected manual sex with another person after injecting 2
b8 In the last month, how many times have you engaged in unprotected manual sex with another person without lubrication 1
Table 1: BBV-TRAQ item categorisations and median key informant ratings (Continued)
Table 2: Demographic and drug use characteristics of IDU sample (N = 419)1
Percentage male 57% (239)
Mean age (SD) 27.8 (8.2)
Employment
employed 22% (93)
student 6% (27)
unemployed 66% (275)
home duties 6% (24)
Mean years since first injection (SD) 9.5 (7.5)
≤ 3 years 23% (97)
> 3 years 77% (318)
Drug most injected in the past month
heroin 71% (296)
amphetamines 22% (91)
other 7% (29)
Frequency of injecting in the past month
weekly or less 20% (85)
more than weekly less than daily 26% (110)
daily or more 54% (224)
Percentage with no Tx experience 28%
Self-report BBV status HCV HBV2 HIV
positive 45% (189) 14% (60) 2% (7)
negative 42% (174) 38% (158) 87% (364)
never tested/not sure 13% (55) 16% (67) 11% (47)
1 Some totals do not sum to 419 due to a small number of non-responders.
2 Includes 32% (133) reporting previous HBV vaccination.Harm Reduction Journal 2008, 5:12 http://www.harmreductionjournal.com/content/5/1/12
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according to their self-reported HCV status to explore
potential predictive validity properties of the scale (see
Table 4). Injecting subscale scores for log two and log five
weights and total scores for log five weights were able to
discriminate between HCV positive and negative IDU in
the expected direction. Effects (as determined by specific F
scores) increased with increasing item weights. Across all
weighting schemes sex and other skin penetration scores
were not significantly different across self-report HCV
groups.
Characteristics of the IDU sample (i.e., mean age, mean
years since first injected; see Table 2) are indicative of a
sample of well-established IDU who may have modified
Table 3: Descriptive statistics for original and weighted BBV-TRAQ scores
Score Mean Median Standard Error Standard Deviation Minimum (number of cases) Maximum
Original BBV-TRAQ Scores
Total Score 26 19 1.13 25.66 0 (31) 135
Injecting 15 9 0.79 16.13 0 (75) 87
Sex 8 2 0.47 9.62 0 (177) 40
Other Skin Penetration 3 2 0.18 3. 60 0 (155) 20
Log 1 Weighted BBV-TRAQ 
Scores
Total Score 77 52 3.63 74.21 0 405
Injecting 59 36 3.12 63.84 0 332
Sex 10 3 0.63 12.83 0 60
Other Skin Penetration 8 5 0.48 9.84 0 55
Log 2 Weighted BBV-TRAQ 
Scores
Total Score 160 105 8.08 165.31 0 805
Injecting 138 82 7.50 153.41 0 770
Sex 10 3 0.66 13.51 0 65
Other Skin Penetration 12 6 0.75 15.39 0 80
Log 5 Weighted BBV-TRAQ 
Scores
Total Score 3,899 2,387 222.17 4,547.68 0 26,095
Injecting 3,745 2,325 217.71 4,456.33 0 25,970
Sex 21 3 1.79 36.72 0 200
Other Skin Penetration 133 25 14.44 295.61 0 2,500
Table 4: Comparisons between self-report HCV status groups for unweighted and weighted BBV-TRAQ total and injecting subscales 
scores
Weights BBV-TRAQ Score F p-value mean difference (HCV positive & negative) 95% CI of the difference
None Injecting subscale 2.46 .141 3 -1 – 7
Total 0.76 .997 2 -4 – 8
Log one Injecting subscale 3.04 .080 15 -1 – 31
Total 1.98 .250 14 -5 – 32
Log two Injecting subscale 3.63 .038 40 2 – 79
Total 2.97 .078 39 -3 – 80
Log five Injecting subscale 4.12 .017 1,293 176 – 2,411
Total 3.86 .023 1,273 132 – 2,414
* Comparisons were made between all HCV groups (i.e., inclusive of 'never tested/not sure' group). To simplify tables only results relevant to the 
focus of this paper have been presented (i.e., 'HCV positive' and 'HCV negative'). No differences were detected between the 'never tested/not sure' 
and other groups.Harm Reduction Journal 2008, 5:12 http://www.harmreductionjournal.com/content/5/1/12
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their risk practices over time. As such, it is potentially
problematic to ask such older and more experienced IDU
about their recent risk behaviours to explore potential pre-
dictive validity properties of the BBV-TRAQ. In order to
account for and moderate the potential effects of a lengthy
injecting career on the relationship between recent risk
practices and HCV status, between groups analyses were
repeated among more recent initiates to injecting (≤ 3
years; n = 96) and younger participants (≤ 25 years; n =
186). When compared to results from the whole sample
(Table 4), both unweighted and weighted BBV-TRAQ
injecting and total scores more clearly differentiated HCV
positive versus negative IDU among younger aged partici-
pants and those that had initiated injecting recently. Con-
sistent with results from the whole sample, the general
trend was for increasing effects with increasing item
weights (Table 5).
Discussion
By retrospectively examining original scale development
and subsequent cross-sectional data, we have devised a
new risk behaviour weighting system that further refines
the BBV-TRAQ instrument and enhances the utility of the
scale for HCV surveillance and prevention evaluation pur-
poses. The approach reported here is consistent with clas-
sical scale development methods [38,41,42]. Both
normative subscale scores and between group (HCV sta-
tus) differences can be used to recommend the choice of a
BBV-TRAQ weighting scheme to measure HCV transmis-
sion risk among IDU.
First, we can examine the contribution of subscales to
total BBV-TRAQ scores in light of the plausible contribu-
tions injecting, sex and other skin penetration behaviours
have to overall risk of HCV infection. The descriptive sta-
tistics presented in Table 3 show average subscale scores
for the weighted and unweighted BBV-TRAQ. In terms of
rank order contribution, both unweighted and log one-
weighted scores can be discounted on the basis of empha-
sising sexual risk practices over other skin penetration
practices, contrary to current opinion [22,25].
Examining the magnitude of subscale contributions, the
sample data presented here shows that the log five-
weighted scale is the most plausible method of modelling
a relative risk profile using the BBV-TRAQ. It is well estab-
lished that injecting risk behaviours (e.g. re-use of used
needles and syringes) represent the greatest contribution
to HCV incidence among IDU. In addition, recent
research suggests 'extremely low or even null' risk of sex-
ual transmission of HCV [30,31]. A log five weighting
scheme that proposes injecting behaviours contributing
in excess of 95% of overall HCV risk among IDU and sex-
ual behaviours contributing less than one percent there-
fore offers a credible overall risk profile.
Estimating the role of other skin penetration practices on
HCV transmission is less clear, with studies showing large
variation in odds ratios attributable to tattooing [26], and
the confounding factors of IDU and unprofessional tat-
tooing, particularly in prison [23,25]. However, given the
low or no risk of HCV sexual transmission, the blood-to-
blood nature of HCV transmission and available epidemi-
Table 5: Comparisons* between self-report HCV status groups and weighted and unweighted BBV-TRAQ total and injecting subscales 
scores among sub-samples of IDU
Sub-sample Weight BBV-TRAQ Score F p-value mean difference (HCV positive & negative) 95% CI of the difference
Initiated injecting ≤ 3 years None Injecting subscale 3.93 .033 10.76 0.63 – 20.88
Total 2.65 .076 14.5 -1.05 – 30.05
Log 1 Injecting subscale 4.48 .016 46.35 6.66 – 86.04
Total 4.19 .018 54.35 7.12 – 101.58
Log 2 Injecting subscale 5.49 .005 120.02 28.99 – 211.04
Total 5.41 .006 130.32 31.25 – 229.39
Log 5 Injecting subscale 7.11 .001 3,696 1,278 – 6,113
Total 7.19 .001 3,752 1,298 – 6,205
Aged ≤ 25 years None Injecting subscale 12.50 <.001 12.97 6.69 – 19.24
Total 8.97 <.001 17.15 7.36 – 26.93
Log 1 Injecting subscale 13.66 <.001 53.88 28.95 – 78.82
Total 12.08 <.001 61.28 31.15 – 91.41
Log 2 Injecting subscale 14.46 <.001 134.11 73.86 – 194.36
Total 13.70 <.001 143.11 77.05 – 209.16
Log 5 Injecting subscale 14.16 <.001 3,915 2,132 – 5,698
Total 13.69 <.001 3,939 2,114 – 5,764
* Comparisons were made between all HCV groups (i.e., inclusive of 'never tested/not sure' group). To simplify tables only results relevant to the 
focus of this paper have been presented (i.e., 'HCV positive' and 'HCV negative'). No differences were detected between the 'never tested/not sure' 
and other groups.Harm Reduction Journal 2008, 5:12 http://www.harmreductionjournal.com/content/5/1/12
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ological evidence, the larger relative risk contribution of
other skin penetration versus sexual risk practices for the
log five weighted scale again appears more realistic.
Second, examining differences in scores between self-
report HCV positive and negative participants also lends
credence to the log five-weighted scale. The log-five
weighted total and injecting sub-scale scores were able to
discriminate between HCV positive and negative IDU
across the entire sample and among sub-groups of
younger and less experienced users. Although requiring
prospective sero-incident data to reliably establish predic-
tive validity among IDU, the cross-sectional data reported
here show log five weighted BBV-TRAQ scores able to dif-
ferentiate levels of risk between HCV positive and nega-
tive participants in the expected direction. These results
show that the application of item weights further refines
the BBV-TRAQ instrument by presenting a more precise
measure of individual risk of contracting HCV across a
broad range of risk behaviours.
Study strengths and weaknesses in relation to other studies
Other studies investigating injecting risk practices associ-
ated with HCV status have reported mixed results. Some
have reported no differences in rates of sharing between
HCV positive and negative IDU [43,44], suggesting that
the targeting of individual risk behaviours may have little
utility. Others [10,45-47] have demonstrated differences
in self-reported injecting risk behaviours according to the
HCV status of IDU.
One possible explanation for the discrepancies in results
is the format of risk behaviour questions asked of IDU.
Those reporting no differences have reported 'catch-all'
responses about the sharing of 'needles and syringes' and
the sharing of 'other equipment' with dichotomised yes/
no response categories. Assuming participants were asked
about their risk behaviours in the same way their
responses were reported and analysed, such measurement
may under-estimate the sharing of injecting equipment.
Indeed, others have found the reported prevalence of
injecting risk practices increases markedly when more
detailed questions about the sharing of specific injecting
equipment are asked [21,48].
Graded response options, as used in the BBV-TRAQ, may
help to limit recall bias and aid in the collection of more
accurate injecting risk practice data [19]. This may be par-
ticularly valid among highly socialised injectors where
'accidental or unnoticed sharing of equipment' might
contribute to HCV transmission risk [49-52]. It is also
possible that multiple domain graded-response instru-
ments such as the BBV-TRAQ might be more likely to trig-
ger the memory of participants' risky injecting behaviours,
reduce recall bias, and subsequently enhance the likeli-
hood of detecting associations between injecting behav-
iours and HCV status. In some studies, graded frequency
scales have been employed with success in multiple ques-
tions about the sharing of individual items used in the
preparation and injecting process [10,45-47].
Implications for clinicians and policymakers
One of the key advantages of having a standardised HCV
risk practice assessment instrument with a weighted scor-
ing system is that it can be applied widely as a measure of
the likelihood of HCV infection. Further validation using
prospective seroincident data could see such a scale used
as a reliable screening tool and as a surrogate indicator of
seroconversion, particularly among IDU, providing a low
cost alternative to serology testing.
For example, the BBV-TRAQ could potentially be adopted
as an outcome measure to evaluate community-based
HCV prevention activities, particularly those that target
high-risk behaviours identified in the BBV-TRAQ, and
inform the development of future education and preven-
tion initiatives in specific settings. Because the scale is
brief, easy to administer and score, and inexpensive to
apply [34,35], adopting the BBV-TRAQ as an outcome
measure overcomes some of the impediments inherent in
evaluating the efficacy of interventions to reduce HCV
transmission. This can be particularly valuable in circum-
stances where resources, time, and the capacity to recruit
and follow large numbers of prevention trial participants
is limited, as can often be the case in community-based or
non-government organisation prevention settings.
In addition, the instrument offers opportunities for
empirically scaled standardised population surveillance
of HCV risk behaviour that go beyond recording dichot-
omised responses indicating if someone had recently
engaged in a risk practice or not. By covering the full range
of injecting and putative HCV risk practices in combina-
tion with protective practices, the BBV-TRAQ also offers
education opportunities to IDU by highlighting risk
behaviours and opportunities for risk reduction. Our
experience using the instrument in standard descriptive
epidemiological studies [37] and recent brief intervention
research [53] indicates that the scale has some impact for
people completing it by accentuating both risk and risk
reduction behaviours. Using BBV-TRAQ normative data,
respondents could be categorised into BBV risk categories
with prevention education tailored accordingly, and
could also be provided with qualitative feedback that
highlights particular risk behaviours that contributed
most to their overall BBV-TRAQ score.
Needless to say the ability for individuals to adopt risk
reduction behaviours is affected by numerous social andHarm Reduction Journal 2008, 5:12 http://www.harmreductionjournal.com/content/5/1/12
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structural factors [15,43,54-56]. Whereas answering ques-
tions about why people adopt or maintain practices that
place them at risk of HCV infection are best explored
using ethnographic and qualitative methods [15], the
BBV-TRAQ would ideally sit alongside such methodolo-
gies by describing what practices people actually engage in
and the frequency with which they occur.
Strengths and weaknesses of the study
A number of methodological limitations need to be con-
sidered when interpreting these results. The most salient
limitation is the reliance upon self-reports to characterise
the HCV status of IDU. Researchers assessing self-report
HCV and HBV status among IDU have reported variable
validity [57,58], however, there is evidence that question-
naire self-administration (the BBV-TRAQ is a self-admin-
istered instrument) increases the reliability of self-report
of behaviours relating to sensitive topics [59]. A recent
study reported that 72% of HCV positive IDU and 46% of
HCV negative IDU were not aware of their HCV status
[60]. This study was, however, conducted across five US
cities and found that use of drug treatment or needle and
syringe programs was associated with increased awareness
of HCV status. Given the more comprehensive nature of
Australia's long-established needle and syringe program
network and a well recognised harm reduction framework
with regards to injecting drugs, one might expect that
knowledge of HCV status among Australian IDU would
be higher than those reported in the US. In addition, the
rates of HCV infection in our sample (45%) are similar to
other comparable Australian samples in which serological
data were collected (e.g., 50%; [6]). However, it is the case
that some anti-HCV positive IDU may have cleared the
virus, whereas others may have mistakenly identified
themselves as HCV positive or negative. The latter misclas-
sification is the most salient here, because associations
between BBV-TRAQ scores and HCV may in fact reflect an
underlying association with awareness of HCV status. Pre-
vious research among Australian IDU showed an associa-
tion between HCV testing and greater knowledge about
BBV transmission and safe injecting [61]. Although such
results would suggest that participants in this study that
were tested for HCV more often or more recently might
more reliably report their HCV status, we cannot assume
that this reliability would be more biased towards self-
report HCV positives or negatives. However, if we assume
similar HCV knowledge characteristics in this sample as
those reported by Treloar et al [61] and also take account
of the HCV status awareness reported above in the US
[60], then it is possible that self-report HCV negatives may
be more likely to report safer injecting practices on the
BBV-TRAQ.
A second limitation is the cross-sectional data collection
and the temporal differences between reporting risk
behaviours and infection. To definitively test the suitabil-
ity of scale weights among IDU (and reliably establish pre-
dictive validity), the BBV-TRAQ would need to be
examined within the context of prospective sero-incident
studies. In most cases, however, changes in risk behaviour
profiles are theoretically likely to favour reductions in risk
over time as IDU are exposed to more harm reduction
messages and more contacts with service providers
[60,62]. Combined with cumulatively more opportunities
for viral transmission over time, such temporal changes
would be more likely to diminish the ability of recent risk
behaviours to predict lifetime exposure to HCV. Indeed,
the analyses conducted on study sub-samples of younger
and less experienced injectors shows an enhanced effect
for the weighted BBV-TRAQ to distinguish between self-
report HCV positive and negative participants (see Table
5). Although not a substitution for a prospective sero-inci-
dent study, examining HCV prevalence among recent ini-
tiates to injecting drugs has previously been used to help
with indirect estimates of HCV incidence [63].
Consistent with results from other studies [10,43], inject-
ing and total weighted BBV-TRAQ risk scores in younger
less experienced IDU were considerably higher (in the
order of three times) than those for the whole sample
combined. Results from prospective cohort work in the
US with recent initiates to injecting drug use suggest that
seroconversion could occur in a quarter of IDU within
approximately two years of initiating injecting and in at
least half within four years of initiation [10]. In addition,
a recent Australian cohort study reported high HCV inci-
dence among new initiates, with mean time to serocon-
version of 1.6 years among participants injecting for less
than two years [64]. In this context, results showing BBV-
TRAQ scores better able to discriminate between HCV
positive and negative recent initiates must give greater
confidence (even if only as a surrogate measure) in the
predictive validity of the weighted BBV-TRAQ. It is likely
that recent injecting risk practices among less experienced
injectors would be somewhat indicative of their lifetime
injecting risk practices, strengthening the connection
between self-reported recent behaviours and lifetime
exposure to HCV.
Finally, the BBV-TRAQ has largely been developed using
IDU cohorts. By testing this weighted instrument with
IDU we are not assuming that this group is the only one
at risk of HCV infection. IDU are, however, the predomi-
nant risk group in many countries [4-6] and therefore con-
stitute the most relevant group from which to begin
establishing the reliability and validity of the weighted
BBV-TRAQ. As described below, testing the validity of the
BBV-TRAQ with other populations is needed. For exam-
ple, testing the suitability of the instrument for non-injec-
tion routes of transmission with people not currentlyHarm Reduction Journal 2008, 5:12 http://www.harmreductionjournal.com/content/5/1/12
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injecting but considered at some level of risk according to
BBV-TRAQ scores.
Unanswered questions and future research
The psychometric development and refinement of a scale
is a necessarily iterative process [38]. Of fundamental
importance in early scale development stages is the estab-
lishment of construct and content validity [65,66], prop-
erties that were emphasised and assiduously developed
during the initial development stages of the BBV-TRAQ
[34,35]. Building on this foundation, this paper presents
data on refinements to the BBV-TRAQ that strengthen its
representation of the underlying construct of BBV risk
assessment – in particular behavioural risk practices for
HCV infection among IDU.
There are two important areas of future research war-
ranted to enhance the properties and utility of the scale.
First, in order to overcome the temporal limitations of
relating lifetime infection with recent risk behaviours and
reliably confirm the predictive validity of the scale, the
BBV-TRAQ needs to be incorporated into prospective inci-
dence studies of HCV transmission that involve the serial
testing over time of baseline HCV-negative IDU. Second,
as the properties of the BBV-TRAQ have largely been
examined in the Australian IDU context with primary her-
oin injectors, subsequent studies are needed to explore
these properties across different cultural, socio-environ-
mental, disease prevalent and drug market conditions.
How scores for the BBV-TRAQ might translate to other
populations with different drug markets (e.g., cocaine
injecting) or different harm reduction capacities (e.g.,
more restricted access to clean injecting equipment) is
unknown. The utility of the instrument for determining
risk of HIV and HBV infection among IDU and other at
risk groups also needs to be examined in populations with
higher disease prevalence. In this regard, no scale develop-
ment occurs with all population groups at one time. As
such, it is important to publish data on this stage of scale
refinement as an iterative step in providing normative
data, upon which data collection and analysis of results
from different populations can be built.
Conclusion
In this study we have refined the BBV-TRAQ to recom-
mend the use of a log five weighted scoring system to
quantify HCV transmission risk among IDU. The applica-
tion of such weights resulted in credible relative risk scores
across subscales and provided a clear distinction between
HCV positive and negative IDU, particularly among
younger and less experienced injectors, for both total and
injecting subscale BBV-TRAQ scores. Reliable, valid and
easy to administer, the BBV-TRAQ is ideal for use in com-
munity settings for research and surveillance purposes,
and for the evaluation of BBV education and prevention
initiatives.
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